Apr 01, 2022 / 12:00PM GMT
Debjit Chattopadhyay - Guggenheim Securities, LLC - Analyst
Good morning and thank you for joining us on day two of Guggenheim's Genomic Medicine and Rare Disease Conference. I am Debjit. I'm one of the analysts representing Guggenheim's therapeutics team.
Today, it's my privilege to host Rocket Pharmaceuticals President and Chief Operating Officer, Kinnari Patel. Thank you so much, Kinnari, and good morning to you.
Kinnari Patel - Rocket Pharmaceuticals, Inc. - COO & President
Good morning and thank you for having us here.
Debjit Chattopadhyay - Guggenheim Securities, LLC - Analyst
Great. So given that we, at Guggenheim, do not have formal coverage of Rocket, it would be very helpful for our audience to get a quick overview from you on Rocket Pharmaceuticals.
Kinnari Patel - Rocket Pharmaceuticals, Inc. - COO & President
Happy to provide that. Rocket is a late-stage integrated gene therapy company. We have treatments that are really focused in rare
Rocket Pharmaceuticals Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Apr 01, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers